Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

The stocks listed here each increased their dividend payments by more than 10% recently. When you think of a great dividend ...

When Eli Lilly & Co. on Tuesday announced pricing and packaging changes for its popular weight-loss drug Zepbound, the drugmaker said it was expanding access for people living with obesity — but ...

U.S. drugmaker Eli Lilly said on Monday it will offer the higher-dose versions of its popular weight-loss drug Zepbound on its website LillyDirect, with shipments starting in early August.

Eli Lilly announced that all approved single-dose vial strengths of Zepbound (tirzepatide), including the highest doses of 12.5 mg and 15 mg, will soon be available through LillyDirect’s Self Pay ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...

Eli Lilly and Co. hosted its first “Ask Me Anything” session on the popular online forum Reddit on Monday, featuring a question-and-answer session with a Lilly executive about insurance ...

Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford treatment.

As we enter a new earnings season, there are several reasons for optimism about the economy. However, potential headwinds ...

Shares in Eli Lilly have weakened after CVS Health, one of the largest pharmacy benefit managers (PBMs) in the US, said it would no longer cover its obesity therapy Zepbound. The shares closed ...